Table 2 Changes from Baseline in Primary and Secondary Outcomes Analyses based on the Intention-To-Treat-Population

AMPS^a ADL motor ability

0.24 (0.09 to 0.39)

0.20 (0.05 to 0.35)

0.04 (-0.16 to 0.25)

0.70

AMPS^a ADL process ability

0.05 (-0.05 to 0.14)

0.02 (-0.07 to 0.12)

0.02 (-0.11 to 0.16)

0.73

ADL-Questionnaire (ADL-Q)

0.09 (-0.01 to 0.20)

0.09 (-0.02 to 0.19)

0.01 (-0.15 to 0.16)

0.90

HAQ-DI^b

-0.09 (-0.19 to 0.01)

0.01 (-0.09 to 0.11)

-0.1 (-0.24 to 0.04)

0.16

  Right

1.43 (0.40 to 2.45)

0.18 (-0.86 to 1.23)

1.24 (-0.22 to 2.71)

0.10

  Left

1.00 (-0.47 to 2.47)

0.36 (-0.71 to 3.44)

1.36 (-0.71 to 3.44)

0.20

  Right

-1.10 (-7.90 to 5.78)

0.57 (-6.27 to 7.41)

-1.63 (-11.30 to 8.04)

0.74

  Left

-5.26 (-12.80 to 2.28)

-0.78 (-8.31 to 6.76)

-4.48 (-15.28 to 6.30)

0.41

  Right

-1.43 (-8.63 to 5.78)

2.87 (-4.33 to 10.07)

-4.30 (-14.49 to 5.00)

0.40

  Left

-1.67 (-9.71 to 6.36)

4.41-(-3.62 to 12.45)

-6.08 (-17.80 to 5.62)

0.30

PainKillers (Number per day)

0.01 (-0.19 to 0.22)

0.01 (-0.22 to 0.19)

0.02 (-0.26 to 0.31)

0.87

DAS28^c

-0.17 (-0.49 to 0.15)

0.26 (-0.10 to 0.53)

-0.39 (-0.84 to 0.07)

0.09

 Tender joint count

-0.51 (-1.83 to 0.82)

0.38 (-0.93 to 1.68)

-0.88 (-2.75 to 0.99)

0.35

 Swollen joint count

0.23 (-0.27 to 0.72)

0.15 (-0.33 to 0.63)

0.08 (-0.61 to 0.77)

0.82

 CRP^d

-0.67 (-2.44-1.11)

1.76 (-0.12-3.63)

-2.42 (-5.00-0.15)

0.06

 Disease activity (VAS)

-7.97 (-15.86—0.09)

-0.70 (-7.93 to 6.53)

-7.27 (-17.97 to 3.43)

0.18

ESR^e

-0.50 (-2.52 to 1.51)

2.30 (0.29 to 4.32)

-2.80 (-5.65 to 0.05)

0.05

 US score: synovial hypertrophy

0.18 (-2.0 to 2.32)

1.83 (-0.22 to 3.89)

-1.66 (-4.63 to 1.32)

0.27

 Synovial perfusion (Doppler)

-0.38 (-2.47 to 1.72)

1.01 (-0.99 to 3.03)

-1.39 (-4.29 to 1.51)

0.34

 UL score total

-1.81 (-5.76 to 2.34)

2.56 (-1.23 to 6.36)

-4.37 (-9.86 to 1.11)

0.12